Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand.
Why it matters
This study tested amyloid PET scans with florbetapir F 18 in people with Alzheimer's disease and younger healthy controls. Visual reads identified 100% of the Alzheimer's patients as amyloid-positive and 100% of controls as amyloid-negative at both doses, and the authors report high test-retest reliability.
-
Noninvasive quantitative approaches provide valid estimates of amyloid-β binding.
Why it matters
This small imaging study tested a new amyloid PET radioligand in six control subjects and 10 patients with Alzheimer disease and found higher binding in the patients. It is an early validation of a scanning tool, not a treatment, cure, or prevention.
-
Alzheimer disease (AD) is the most common type of dementia worldwide.
Why it matters
This imaging study found the most hippocampal atrophy and ventricular enlargement in Alzheimer's disease compared with cognitively normal elderly, with intermediate levels in mild cognitive impairment, and found age effects independent of Alzheimer's pathology. It is about measuring brain changes, not about treating, curing, or preventing the disease.
-
Some genes contribute to AD pathogenesis in both white and African American cohorts, although it is unclear whether the causal variants are the same.
Why it matters
This genetic study in African Americans found associations with Alzheimer disease in the APOE region and in several other genes, with some differences from findings in white populations. It identifies genetic associations and does not provide a treatment, cure or prevention.
-
In this work we use a large scale regularization approach based on penalized logistic regression to automatically classify structural MRI images (sMRI) according to cognitive status.
Why it matters
This study used penalized logistic regression to classify structural MRI images of 49 cognitively normal and 49 Alzheimer disease subjects, achieving higher accuracy with gray matter volume maps than white matter maps. It is a machine learning classification method for diagnosing Alzheimer disease, not a treatment, cure or prevention.
-
Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD).
Why it matters
This review discusses oxidative stress in mild cognitive impairment and Alzheimer's disease and proposes raising levels of the antioxidant glutathione using N-acetyl-cysteine or gamma-glutamylcysteine ethyl ester as a possible treatment approach. It presents this as a potential strategy rather than an established therapy.
-
There is increasing evidence that the consumption of flavonoid-rich foods can beneficially influence normal cognitive function.
Why it matters
Flavonoid-rich foods such as green tea, blueberry and cocoa have been shown to reduce Alzheimer-like pathology and reverse cognitive deficits in rodent models. These are animal findings only, so it is not yet known whether they help prevent or treat dementia in people.
-
Parental death during childhood is associated with higher prevalence of AD, with different critical periods for father's versus mother's death, with strength of these associations attenuated by remarriage of the widowed parent.
Why it matters
This study examined whether early parental death was linked to higher risk of Alzheimer's disease in offspring. It found that mother's death during adolescence was associated with higher risk, but it does not test any treatment or cure.
-
AD, DS, and DSAD brains also have reduced mtDNA ND6 mRNA levels, altered mtDNA copy number, and perturbed Aβ metabolism.
Why it matters
This review argues that problems with mitochondria, the cell's energy producers, may explain both Alzheimer's and Parkinson's disease, citing genetic and mouse data. It proposes a unifying theory rather than reporting a proven treatment or cure.
-
47/100
Debate exists regarding differences in the prevalence of Alzheimer disease (AD) in African Americans and Hispanics in the United States, with some evidence suggesting that the prevalence of AD may be considerably higher in these groups than in non-Hispanic whites.
Why it matters
This 2011 review notes that "debate exists" over whether Alzheimer's is more common in African American and Hispanic people in the US than in non-Hispanic white people, while minority patients "often receive delayed diagnosis or inadequate treatment." It links these gaps to biological risk factors such as genetics and cardiovascular disease, and to cultural factors including views of normal ageing, access to care and trust in the medical system. It also warns that widely used cognitive screening tests may carry racial bias, which adjusting for literacy "has the potential to mitigate." It is a narrative review with no new data and reports no treatment.
-
Astrocytes contribute to a variety of functions in the brain, including homeostasis, synapse formation, plasticity, and metabolism.
Why it matters
This study characterized gene expression in astrocytes from postmortem brain tissue at different stages of neurofibrillary tangle pathology. It describes changes in astrocyte genes related to Alzheimer pathology and APOE genotype, and reports no treatment, cure or prevention.
-
PVC was shown to improve the quantitative accuracy of regional analysis performed on amyloid PET images.
Why it matters
This study found that partial volume correction improved the quantitative accuracy of regional analysis on amyloid PET images, with VC deconvolution showing the worst recovery of grey matter values. It is a technical imaging methods study and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Hippocampal atrophy and amyloid deposition seem to dissociate during the evolution of MCI, the atrophy increasing clearly and [(11)C] PiB retention changing modestly when conversion to AD occurs.
Why it matters
In patients with mild cognitive impairment followed for 2 years, those who converted to Alzheimer disease had greater PiB retention at baseline, and amyloid retention changed modestly while hippocampal atrophy increased. This concerns imaging and disease progression, not treatment, cure or prevention.
-
LSN analysis revealed that interconnectivity patterns of brain regions can be used to classify subjects with AD, those with aMCI, and CN subjects.
Why it matters
This small study used resting-state functional MRI and network analysis to distinguish people with Alzheimer disease, amnestic mild cognitive impairment, and normal cognition with fairly high accuracy. It concerns classification and diagnosis only, not treating, curing, or preventing the disease.
-
Alzheimer disease (AD) is a neurodegenerative disorder in which oxidative stress is a key hallmark.
Why it matters
This review describes how oxidative stress from mitochondria and microglia-related inflammation may contribute to Alzheimer's disease. It discusses possible strategies but reports no tested treatment or prevention.
-
The main aim of the present study was to compare volume differences in the hippocampus and parahippocampal gyrus as biomarkers of Alzheimer's disease (AD).
-
Severity of psychiatric symptoms, behavioral disturbances, and patients' quality of life are the main correlates of caregivers' experience burden.
Why it matters
In 421 outpatients with Alzheimer's disease, more severe psychiatric and behavioral problems, decreased quality of life, and lower functional capability were linked to higher caregiver burden and depression, and six-month improvements in symptoms and quality of life were linked to decreased burden. It concerns caregiver burden and does not test any treatment, cure, or prevention for the disease itself.
-
BPs of [(11)C](R)PK11195 and [(11)C]PIB were significantly higher in the parietotemporal regions of AD patients than in ten healthy controls.
Why it matters
Using PET scans in eleven people with early Alzheimer's and ten healthy controls, researchers found that both microglial activation (the brain's immune cells switching on) and amyloid deposits were higher in parietotemporal regions of patients. Dementia scores correlated with microglial activation but not with amyloid, and in the posterior cingulate cortex the two markers were negatively correlated. The authors suggest amyloid build-up is not always the primary cause of microglial activation in early Alzheimer's.
-
Iron influx increases the translation of the Alzheimer amyloid precursor protein (APP) via an iron-responsive element (IRE) RNA stem loop in its 5'-untranslated region.
Why it matters
In human neural cells, the protein IRP1 selectively bound to a specific RNA structure in the amyloid precursor protein transcript, linking iron regulation to APP production. This is laboratory and tissue-based work on how APP is made, not a demonstrated treatment or prevention strategy.
-
The aim of this study was to investigate the dynamics of four of the most validated biomarkers for Alzheimer's disease (AD), cerebro-spinal fluid (CSF) Abeta 1-42, tau, hippocampal volume, and FDG-PET, in patients at different stage of AD.
Why it matters
This study found that Alzheimer's disease biomarkers such as cerebrospinal fluid Abeta 1-42, tau, hippocampal volume, and FDG-PET follow different patterns of change over the course of the disease. The findings describe how biomarkers change over time and do not report on treating, curing, or preventing Alzheimer's disease.
-
47/100
Olfactory dysfunction is common in Alzheimer disease (AD) and other neurodegenerative diseases.
Why it matters
This study looked at amyloid-beta and paired helical filament-tau pathology in olfactory epithelium tissue from 79 postmortem cases with Alzheimer's disease and other conditions. It aimed to establish how common and specific these findings are and how they relate to brain pathology, but it does not provide a treatment, cure or prevention for Alzheimer's disease.
-
Volume and change in volume of the hippocampus are both important markers of Alzheimer's disease (AD).
-
We investigated oxidative stress in human postmortem frontal cortexfrom individuals characterized as mild cognitive impairment (n= 8), mild/moderate Alzheimer disease (n = 4), and late-stage Alzheimer disease (n = 9).
Why it matters
In postmortem frontal cortex, oxidative markers increased and antioxidants declined across mild cognitive impairment and Alzheimer's disease, with the highest changes in the synaptosomal fraction, and oxidative marker levels correlated with Mini-Mental Status Examination scores. This is a descriptive tissue study and reports no treatment, cure or prevention.
-
HIV-associated neurologic disorders (HAND) continue to develop in many patients with HIV.
Why it matters
This study measured cerebrospinal fluid amyloid and other markers in people with HIV-associated neurologic disorders and compared them with dementia of the Alzheimer type. It is a biomarker comparison and does not show any treatment, cure, or prevention for Alzheimer disease.
-
Synapse loss is strongly correlated with cognitive impairment in Alzheimer's disease (AD).
Why it matters
In mice engineered to develop Alzheimer's-like changes, treatments that restored certain cell signaling or proteasome function reversed the loss of dendritic spines, the connections between neurons. This was an animal study, so it is not yet known whether the same approach could reverse spine loss in people.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
- A Comprehensive, Community‐Engaged Recruitment Strategy to Increase Minority Representation in New IDEAS – an Amyloid Imaging Study
- In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults
- Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease
- Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review
- Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?
- Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities
- Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
- Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease
- An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease